Effects of tissue plasminogen activator for acute ischemic stroke at one year

New England Journal of Medicine

Volumn 340, Issue 23, 1999, Pages 1781-1787

  Kwiatkowski, Thomas G ^a   Libman, Richard B ^a   Frankel, Michael ^b   Tilley, Barbara C ^c   Morgenstern, Lewis B ^d   Lu, Mei ^e   Broderick, Joseph P ⁱ   Lewandowski, Christopher A ^e   Marler, John R ^f   Levine, Steven R ^g   Brott, Thomas ^h  

^a LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^e HENRY FORD HEALTH SCIENCES CENTER   (United States)

^f NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^g WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h MAYO CLINIC   (United States)

ⁱ NONE

Author keywords

[No Author keywords available]

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; ORAL DRUG ADMINISTRATION; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; ACUTE DISEASE; BRAIN ISCHEMIA; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; MULTIVARIATE ANALYSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 0033542395     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199906103402302     Document Type: Article

References (27)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7.
2. Lyden P, Brott T, Tilley B, et al. Improved reliability of the NIH Stroke Scale using video training. Stroke 1994;25:2220-6.
3. The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group. A systems approach to immediate evaluation and management of hyperacute stroke: experience at eight centers and implications for community practice and patient care. Stroke 1997;28:1530-40.
4. Mahoney FI, Barthel DW. Functional evaluation: the Barthel index. Md Med J 1965;14(2):61-5.
5. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJA, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19:604-7.
6. Teasdale G, Knill-Jones R, van der Sande J. Observer variability in assessing impaired consciousness and coma. J Neurol Neurosurg Psychiatry 1978;41:603-10.
7. Shinar D, Gross CR, Bronstein KS, et al. Reliability of the activities of daily living scale and its use in telephone interview. Arch Phys Med Rehabil 1987;68:723-8.
8. Korner-Bitensky N, Wood-Dauphince S, Siemiatycki J, Shapiro S, Becker R. Health-related information postdischarge: telephone versus face-to-face interviewing. Arch Phys Med Rehabil 1994;75:1287-96.
9. Candelise L, Pinard G, Aritzu E, Musicco M. Telephone interview for stroke outcome assessment. Cerebrovasc Dis 1994;4:341-3.
10. Tilley BC, Marler J, Geller NL, et al. Use of a global test for multiple outcomes in stroke trials with application to the National Institute of Neurological Disorders and Stroke t-PA Stroke Trial. Stroke 1996;27: 2136-42.
11. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-48.
12. Generalized efficacy of t-PA for acute stroke: subgroup analysis of the NINDS t-PA Stroke Trial. Stroke 1997;28:2119-25.
13. Sacco RL, Shi T, Zamanillo MC, Kargman DE. Predictors of mortality and recurrence after hospital cerebral infarction in an urban community: the Northern Manhattan Stroke Study. Neurology 1994;44:626-34.
14. Sacco SE, Whisnant JP, Broderick JP, Phillips SJ, O'Fallon WM. Epidemiological characteristics of lacunar infarcts in a population. Stroke 1991;22:1236-41.
15. Sacco RL, Wolf PA, Kannel WB, McNamara PM. Survival and recurrence following stroke: the Framingham Study. Stroke 1982;13:290-5.
16. Hacke W, Schwab S, Horn M, Spranger M, De Georgia M, von Kummer R. 'Malignant' middle cerebral artery territory infarction: clinical course and prognostic signs. Arch Neurol 1996;53:309-15.
17. Yusuf S, Wittes J, Probstfield J, Tyroler H. Analysis and interpretations of treatment effects in subgroups of patients in randomized clinical trials. JAMA 1991;266:93-8.
18. Multicentre Acute Stroke Trial - Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet 1995;346:1509-14.
19. The Multicenter Acute Stroke Trial - European Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 1996;335:145-50.
20. Donnan GA, Davis SM, Chambers BR, et al. Streptokinase for acute ischemic stroke with relationship to time of administration. JAMA 1996; 276:961-6.
21. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study. JAMA 1995;274:1017-25.
22. Frankel MR. Thrombolytic therapy in acute ischemic stroke. N Engl J Med 1997;336:65.
23. Thrombolytic therapy for acute ischemic stroke: summary statement: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1996;47:835-9.
24. Adams HP Jr, Brott TG, Furlan AJ, et al. Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 1996;27:1711-8.
25. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998;352:1245-51.
26. Fagan SC, Morgenstern LB, Petitta A, et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. Neurology 1998;50:883-90.
27. Chiu D, Krieger D, Villar-Cordova C, et al. Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice. Stroke 1998;29:18-22.